Showing 2461-2470 of 4264 results for "".
The Hidradenitis Suppurativa Therapeutic Pipeline
https://practicaldermatology.com/topics/rare-disease/the-hidradenitis-suppurativa-therapeutic-pipeline/54824/Though treatment options are currently limited, the pipeline for HS therapeutics is active with numerous medications in development.Precision Medicine for AD
https://practicaldermatology.com/columns/atopic-dermatitis-essentials/precision-medicine-for-ad/54826/A Q & A with Derek MaetzoldA Busy Time in the Field
https://practicaldermatology.com/issues/januaryfebruary-2026/a-busy-time-in-the-field/54452/Should Children and Adolescents Be Screened for Primary Hyperhidrosis?
https://practicaldermatology.com/issues/novemberdecember-2025/should-children-and-adolescents-be-screened-for-primary-hyperhidrosis/48891/Primary hyperhidrosis (PH) is a chronic, often underreported and underdiagnosed condition without a cure. While it frequently runs in families, the exact etiology is unknown.Can Prescription Hyperhidrosis Treatments Help Mitigate Symptoms?
https://practicaldermatology.com/topics/rare-disease/can-prescription-hyperhidrosis-treatments-help-mitigate-symptoms/39997/Remaking Ourselves: Aesthetic Medicine That Is Regenerative
https://practicaldermatology.com/issues/october-2025/remaking-ourselves-aesthetic-medicine-that-is-regenerative/39752/Apocrine Hidrocystoma of the Axilla
https://practicaldermatology.com/issues/october-2025/apocrine-hidrocystoma-of-the-axilla-an-illustrative-case-and-literature-review/39757/An Illustrative Case and Literature ReviewPreparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Mergers and Acquisitions in Derm and Aesthetics: Market Outlook
https://practicaldermatology.com/issues/september-2025/mergers-and-acquisitions-in-derm-and-aesthetics-market-outlook/37631/We took a deeper look into the dermatology and aesthetics mergers and acquisitions (M&A) market in a conversation with two of our team members, Drew Thomas and Jordan Frickle, who are closely involved in this sector. The following discussion brings together their perspectives on current trends,First Reported Case of Red Face Response to Tralokinumab in the United States
https://practicaldermatology.com/issues/september-2025/first-reported-case-of-red-face-response-to-tralokinumab-in-the-united-states/37639/The chronic nature of atopic dermatitis (AD), which currently affects approximately 10.8% of children and 7.3% of adults in the United States,1 makes long-term management challenging.